Epigenomics AG

Epigenomics AG was founded in Berlin in 1998 by Dr. Alexander Olek. From its beginning, the company concentrated on the medical applications of DNA methylation, an epigenetic modification that can provide measurable molecular signatures associated with disease. Its scientific and commercial objective was to identify methylation patterns that could be converted into reproducible diagnostic tests, especially for cancer. Around the same period, ORCA Biosciences was founded in Seattle. The two businesses merged in 2000, giving Epigenomics a transatlantic structure that included operations in Germany and the United States. The resulting company continued to work on DNA-methylation biomarkers and on technologies intended to analyze methylation in blood and other body fluids. This work was important to the company’s strategy because minimally invasive sampling can make molecular testing easier to integrate into clinical pathways than procedures requiring surgical tissue collection. Epigenomics became a publicly traded company in 2004 through a listing on the Frankfurt Stock Exchange. The offering raised €41.6 million, providing capital for the company’s diagnostic research and development activities. After the listing, Epigenomics retained a workforce in Berlin and maintained its U.S. presence through Epigenomics Inc. in Seattle. The company’s research portfolio developed around several oncology biomarkers. SEPT9 became the best-known program and was associated with blood-based detection of colorectal cancer. Epigenomics developed Epi proColon, a plasma test measuring methylation of the SEPT9 promoter as an aid in the early detection of colon cancer. The company also developed Epi proLung, which measures SHOX2 methylation in bronchial lavage fluid to support the diagnostic workup of patients suspected of having lung cancer. A further research contribution involved PITX2 methylation in prostate tissue, where the marker was studied for prognostic use. These programs reflected a broader effort to establish DNA methylation as a practical basis for clinical laboratory testing. Epigenomics pursued more than a direct-product model. It licensed the SEPT9 biomarker and selected methylation technologies to Quest Diagnostics and ARUP Laboratories in the United States and to Warnex Laboratories in Canada. Those organizations independently developed laboratory-developed tests and offered SEPT9 testing services. Epigenomics also entered a strategic relationship with Abbott Molecular to develop an in-vitro diagnostic kit based on SEPT9. Abbott subsequently launched a CE-marked European test under the mS9 brand. The referenced company material distinguishes these independently developed licensee tests from Epigenomics’ own products and does not guarantee their performance, while noting that reported clinical-validation results were similar. The company’s published profile described two CE-marked in-vitro diagnostic products, Epi proColon and Epi proLung, while stating that they were not then available in the United States. Its scientific program has included discovery and validation of additional methylation biomarkers, development of methods for analyzing methylation in blood and other body fluids, and efforts to make methylation testing suitable for routine clinical laboratories. The same material cited more than 60 peer-reviewed scientific publications over a ten-year period as evidence of the company’s contribution to the field. The available references do not establish a complete current product catalog, current executive roster, present commercial footprint, or the latest status of individual products, so those areas require verification from current company filings or other up-to-date sources.

1. 2004Frankfurt Stock Exchange listing

   Epigenomics became publicly traded in Frankfurt and raised €41.6 million through the listing.

   Source
2. 2000Merger with ORCA Biosciences

   Epigenomics and Seattle-based ORCA Biosciences merged, establishing the company’s continuing German-American operating structure.

   Source
3. 1998Company founded in Berlin

   Dr. Alexander Olek founded Epigenomics in Berlin to develop medical applications of DNA-methylation biomarkers.

   Source
4. Launch of Epi proColon and Epi proLung

   The company developed and launched two CE-marked in-vitro diagnostic products based on SEPT9 and SHOX2 methylation biomarkers.

   Source
5. SEPT9 licensing and Abbott partnership

   Epigenomics licensed SEPT9-related technology to laboratories in the United States and Canada and partnered with Abbott Molecular on a European diagnostic kit.

   Source

A specialist molecular-diagnostics company focused on translating DNA-methylation biomarkers into oncology screening, detection, and clinical decision-support tests.

• Epi proColonColorectal cancer molecular diagnostic

  Epi proColon is a CE-marked in-vitro diagnostic test designed to measure methylation of the SEPT9 promoter in a plasma sample. The result is intended to aid the early detection of colorectal cancer. The product represents Epigenomics’ effort to provide a blood-based alternative or complement to conventional colorectal-cancer screening approaches. The referenced material states that the product was not then available in the United States.

• Epi proLungLung cancer molecular diagnostic

  Epi proLung is a CE-marked in-vitro diagnostic product that measures methylation of the SHOX2 gene in bronchial lavage fluid. It is intended to assist the diagnostic workup of patients suspected of having lung cancer. The test reflects Epigenomics’ broader focus on applying DNA-methylation signatures to clinically relevant oncology decisions and on using body-fluid samples for molecular analysis. Current availability and commercial status are not established by the supplied references.

• mS9SEPT9-based colorectal cancer diagnostic

  mS9 is a CE-marked European in-vitro diagnostic product launched by Abbott Molecular under a strategic relationship with Epigenomics. It is based on the SEPT9 methylation biomarker for colorectal-cancer detection. The product illustrates Epigenomics’ partnership and licensing model, in which its biomarker science and methylation technologies could be incorporated into products developed and commercialized by a larger diagnostics company.

• SEPT9 laboratory-developed testsLaboratory-developed molecular test

  Epigenomics licensed the SEPT9 biomarker and certain DNA-methylation technologies to Quest Diagnostics and ARUP Laboratories in the United States and Warnex Laboratories in Canada. These laboratories independently developed laboratory-developed tests and provided SEPT9 testing services. The referenced material treats these tests as licensee-developed offerings rather than products directly developed by Epigenomics.

• 2004Public listing and capital raisingStrategy

  Epigenomics sought public-market financing for its biomarker discovery, assay-development, and diagnostic commercialization activities.

  What changed. The company listed on the Frankfurt Stock Exchange and raised €41.6 million.

  Aftermath. The listing established Epigenomics as a publicly traded specialist molecular-diagnostics company.

  Capital raised. €41.6 million raised (2004 public listing)

  Source
• 2000Merger with ORCA BiosciencesM&A

  Epigenomics and ORCA Biosciences were both developing applications of molecular and DNA-methylation science in Berlin and Seattle.

  What changed. The companies merged, creating a combined business with activities in Germany and the United States.

  Aftermath. The merger provided the basis for Epigenomics’ transatlantic operating structure and continued oncology diagnostics focus.

  Source
• Licensing and strategic partnership for SEPT9M&A

  Epigenomics needed routes to broader clinical use for its SEPT9 biomarker beyond products developed and sold directly by the company.

  What changed. It licensed SEPT9-related technology to Quest Diagnostics, ARUP Laboratories, and Warnex Laboratories, and entered a strategic partnership with Abbott Molecular for an in-vitro diagnostic kit.

  Aftermath. The licensees developed laboratory tests, while Abbott launched the CE-marked mS9 product in Europe.

  Source

1. Epigenomics AG